Grinage Bradley D
Department of Psychiatry and Behavioral Sciences, University of Kansas School of Medicine-Wichita, Wichita, Kansas 67214-3199, USA.
Am Fam Physician. 2003 Dec 15;68(12):2401-8.
Although post-traumatic stress disorder (PTSD) is a debilitating anxiety disorder that may cause significant distress and increased use of health resources, the condition often goes undiagnosed. The lifetime prevalence of PTSD in the United States is 8 to 9 percent, and approximately 25 to 30 percent of victims of significant trauma develop PTSD. The emotional and physical symptoms of PTSD occur in three clusters: re-experiencing the trauma, marked avoidance of usual activities, and increased symptoms of arousal. Before a diagnosis of PTSD can be made, the patient's symptoms must significantly disrupt normal activities and last for more than one month. Approximately 80 percent of patients with PTSD have at least one comorbid psychiatric disorder. The most common comorbid disorders include depression, alcohol and drug abuse, and other anxiety disorders. Treatment relies on a multidimensional approach, including supportive patient education, cognitive behavior therapy, and psychopharmacology. Selective serotonin reuptake inhibitors are the mainstay of pharmacologic treatment.
尽管创伤后应激障碍(PTSD)是一种使人衰弱的焦虑症,可能会导致严重的痛苦并增加医疗资源的使用,但这种疾病常常未被诊断出来。在美国,PTSD的终生患病率为8%至9%,约25%至30%的重大创伤受害者会患上PTSD。PTSD的情绪和身体症状分为三类:反复体验创伤、明显回避日常活动以及觉醒症状增加。在确诊PTSD之前,患者的症状必须严重干扰正常活动且持续超过一个月。大约80%的PTSD患者至少有一种共病精神障碍。最常见的共病障碍包括抑郁症、酒精和药物滥用以及其他焦虑症。治疗依赖于多维度方法,包括支持性患者教育、认知行为疗法和心理药理学。选择性5-羟色胺再摄取抑制剂是药物治疗的主要手段。